🇺🇸 FDA
Pipeline program

Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]

19-10020997

Phase 1 small_molecule active

Quick answer

Glycerol Phenylbutyrate 1100 MG/ML [Ravicti] for STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder is a Phase 1 program (small_molecule) at Connect Biopharma Holdings Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Connect Biopharma Holdings Ltd
Indication
STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials